Clinical trials: Atorvastatin
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypercholesterolemia
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy.
- Trial name
- NCT00690443
- Testing
- Atorvastatin, AEGR-733
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.
- Trial name
- NCT03801733
- Testing
- Vadadustat, Simvastatin, Rosuvastatin
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Dyslipidaemias, Dyslipidemias
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
- Trial name
- NCT01218204
- Testing
- 10mg atorvastatin, 80mg atorvastatin, 100mg GSK1292263
- Where
- 21 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Healthy Male Subjects
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
primary object : Evaluate pharmacokinetic drug-drug interaction of Candesartan and Atorvastatin
- Trial name
- NCT02609711
- Testing
- Candesartan cilexetil
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Healthy
Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs
A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied DDI Probe Compounds.
- Trial name
- NCT02641899
- Testing
- ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Intarcia Therapeutics
Dyslipidemias
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL
- Trial name
- NCT00644709
- Testing
- Atorvastatin
- Where
- 15 sites in Belgium
- Volunteers
- 196 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition
This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate and atorvastatin calcium) tablets 10mg/80mg…
- Trial name
- NCT02292069
- Testing
- Amlodipine besylate/Atorvastatin calcium
- Where
- India
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hypercholesterolemia
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
The purpose of this study is to evaluate the efficacy of Atorvastin vs Simvastatin in decreasing LDL-C in diabetic subjects with hypercholesterolemia at the end of the treatment phase.
- Trial name
- NCT00141141
- Testing
- Atorvastatin, Simvastatin
- Where
- 35 sites in Italy
- Volunteers
- 383 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
- Trial name
- DESCARTES (NCT01516879)
- Testing
- Evolocumab, Atorvastatin, Ezetimibe
- Where
- 96 sites in United States, Australia and 7 more
- Volunteers
- 905 people
- Sponsor
- Amgen
Drug-Interactions
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT04764851
- Testing
- ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Healthy
Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects
The purpose of the study is to assess the pharmacokinetic interactions between atorvastatin and metformin single or co-administered in healthy volunteers
- Trial name
- NCT01765023
- Testing
- Period I : atorvastatin, Period II : atorvastatin and metformin, Period I : metformin, Period II : atorvastatin and metformin
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Hypercholesterolemia in Coronaory Heart Disease
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary…
- Trial name
- HS-25-III-02 (NCT03433196)
- Testing
- HS-25 and Atorvastatin, Atorvastatin
- Volunteers
- 255 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Cardiovascular Disorder, Diabetes Mellitus
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
The purpose of this study is to determine the efficacy of switching to a combination tablet ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose in those patients who have cardiovascular…
- Trial name
- NCT00862251
- Testing
- ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
This is a 2-part, Phase 1, placebo-controlled, double-blind, randomized, single and multiple ascending dose study. CAT-2054 will be administered either as an uncoated capsule (CAT-2054) or a coated capsule (CAT-2054-C).
- Trial name
- NCT02374047
- Testing
- CAT-2054, CAT-2054-C, Atorvastatin
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Catabasis Pharmaceuticals
Dyslipidemias, Cardiovascular Risk Factor
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican adult population.
- Trial name
- NCT03696940
- Testing
- L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg, Atorvastatin 10mg
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Grossman, S.A.
Hypercholesterolemia, Familial, Hyperlipidemia
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial…
- Trial name
- NCT00134485
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 41 sites in United States, Australia and 7 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Eze/Simva Switch Study in Diabetics (0653A-807)
A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.
- Trial name
- NCT00541697
- Testing
- MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks
- Volunteers
- 648 people
- Sponsor
- Organon and Co
Type 1 Diabetes
DIATOR-Diabetes Intervention With Atorvastatin
Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator.
- Trial name
- NCT00974740
- Testing
- Atorvastatin
- Where
- 12 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Healthy Participants
A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants
The purpose of this study is to evaluate effects of steady-state concentrations (constant concentration of medication in the blood) of TMC435 on the single dose pharmacokinetics (what the body does to the medication) of…
- Trial name
- NCT01689623
- Testing
- TMC435, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC